News: The global oncology platform

The newly launched Advances in Modern Oncology Research (AMOR) journal aims to establish itself as one of the global platforms for oncology publications. It seeks to deliver significant original research articles, review articles and clinical studies in all disciplines of Modern Oncology, and to provide an effective communication and information exchanging platform for a broad audience of oncologists, surgeons, medical researchers and professionals working in the field.

 

In an interview, AMOR editor-in-chief Dr. Omar Abdel-Rahman who is also a professor of clinical oncology from the Faculty of Medicine, Ain Shams University, Cairo, Egypt, spoke of AMOR’s uniqueness of appeal and his great hopes for the budding international journal.

 

dr omar2Dr. Omar Abdel-Rahman, M.B.B.Ch, M.Sc, MD, is an accomplished professional in the oncology field with over three dozen published scientific papers in various oncology journals as well as three books on oncology. Dr. Omar is presently a member in various prominent oncology societies such as European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Association of Cancer Research (EACR) and more. He has presented papers at several conferences such as the ESMO World Congress, is actively involved in several projects such as a coordinator for the ASU-YOUTH (Ain Shams University –Young Oncologist Union educational program), and is also currently a member of the writing committee of the first ever Egyptian national guidelines for hepatocellular carcinoma (HCC) developed by the Egyptian society of liver cancer.


 

He received the Union for International Cancer Control (UICC) international cancer technology transfer fellowship (ICRETT) at the investigational new drugs unit in the European Institute of Oncology, Milan, Italy, as well as the EACR travel fellowship to Christie NHS trust, Manchester, UK, in addition to being an invited reviewer to a number of peer reviewed journals and scientific organizations (including the Italian ministry of health scientific competition 2015).

 

Q: What is AMOR and why is there a need of such an oncology journal?

Dr. Omar: We felt that there is a need for a platform that combines the specialities in dealing with the treatment of cancer including oncology, pathology, radiology, and all those dealing with cancer-related diagnosis and treatment. We feel that we are in need of a universal platform that can combine all the specialities and all interests in one platform that can help transform the most recent research development into application for the entire world.

 

How is AMOR different from other journals?

I think we are different in many terms and aspects. We are open to all geographical areas. We have a jumbo editorial board: currently, there are more than 390 editorial board members from approximately 50 countries, and we are combining specialties from different areas, different countries and different interests. I think we provide a more global overview of oncology that is not restricted to, for example, European or North American viewpoints of oncology practice like the ones represented by the majority of oncology journals worldwide.

1

In terms of the medical community itself, what do you hope AMOR can achieve?

We hope that the journal can accommodate high quality publications and submissions from different geographical locations and specialities from all over the world. We hope to transform all high quality submissions into an elegant publication which can bring forward recent developments in cancer diagnosis and treatment to all interested biomedical specialists.

 

How can prospective authors benefit from AMOR?

Prospective authors can benefit from a neutral, rigorous, fast-tracked, high-quality peer reviewing process. They can benefit from rapid turnover or rapid decisions [of manuscript acceptance or rejection] from the editorial office. They can also benefit from being a member of a global community of oncology specialists from different background and different geographical and social background. So I think it’s great for any prospective author to publish his or her high-quality publication in AMOR.

 

How do AMOR editorial board members (EBMs) benefit from being part of the group?

Firstly, the APC for the first manuscript submission from every EBM is waived. Subsequently, discounts will be given accordingly. Please refer to AMOR's website for more information.

Secondly, those editorial board members with the highest participation and the highest activity within AMOR in the terms of submissions, reviews and other activities will be recognized by the editorial board and we are discussing how to best reward them for their generous effort.

Thirdly, to be a part of this global community of EBMs and new experience of multinational multi-specialists group of cancer-related specialists, I think it is very good to communicate and transfer this knowledge to each other.

 

As editor-in-chief, what are your personal hopes for AMOR in short term and long term?

In the short term, I hope we will finish our PubMed and other database registration, and I hope we maintain a good rate of submissions and high quality publications.

On the long term, I hope that AMOR could become a role model for how a global community of oncology specialists and cancer-related specialists can produce high quality publications in a manner that is not subject-restricted, that is not geographically restricted and that is not ethnically restricted.

 

How did you personally get involved in AMOR?

I got an email from the PiscoMed, from the company that produces AMOR, and I was interested merely by the idea [of Amor]. So I replied positively, and we kept in contact via email communication and Skype and interviews with PiscoMed. I believe that we are on the same wavelength in terms of producing a good quality, global, multinational, multi-specialist publication. I feel that we are in the same mode of thinking. So we got an agreement for me to be the EIC of AMOR, and I hope that this fruitful experience and collaboration continues for the benefit of AMOR and the benefit of the scientific community.

 

Now that AMOR is going into the 2nd issue of the 1st volume, how is it doing so far in your opinion?

I think it is doing very good for a newly launched journal, and I think it will be doing even better in the coming months as an additional tool in itself and as a real scientific publication that accommodates different specialities and different geographical backgrounds; and it is being transformed into our original message of a combined platform for all those who are interested in cancer-related treatment and diagnosis.

 

Researchers, scientists and other professionals of the oncology field who are interested in publishing their papers or in becoming an editorial board member of the Advances in Modern Oncology Research, or otherwise have additional questions about how AMOR could help their professions are all highly encouraged to contact our editorial office at amor@piscomed.com.